

해외 바이오의약품 임상 현황 ('23년 8월 1주)

한국바이오의약품협회, 2023.08.08.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2023.07.31.~2023.08.06.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 62건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05957367	A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies	Drug: DCC-3116 Drug: Ripretinib Drug: Cetuximab Drug: Encorafenib	Deciphera Pharmaceuticals LLC Pfizer	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05957367
NCT05734560	D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients	Drug: D2C7-IT Drug: 2141-V11	Darell Bigner Rockefeller University Duke University	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05734560
NCT05669352	A Phase 1/2 Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab Following Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases	Drug: CA-4948 Drug: Pembrolizumab	University of Florida Merck Sharp & Dohme LLC	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05669352
NCT05486481	Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)	Drug: Venetoclax Drug: Dexamethasone Drug: Daratumumab	Sandy Wong, MD Janssen Pharmaceuticals AbbVie University of California, San Francisco	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05486481
NCT05159453	Dose Response Study of Transdermal Human Insulin in Patients	Biological: Human Insulin Device: Finger-actuated, Metered Pump Sprayer	Transdermal Delivery Solutions Corp Langford Research Institute, Inc.	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05159453
NCT04129515	NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis	Device: NovoTTF-200A Drug: Pembrolizumab	Brown University NovoCure Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04129515
NCT03520751	Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A	Drug: scAAV1.tMCK.NTF3	Nationwide Children's Hospital	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT03520751
NCT02522611	Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain	Drug: Resiniferatoxin	National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of Health Clinical Center (CC)	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT02522611
NCT05878860	ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis	Biological: ATSN-201	Atsena Therapeutics Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05878860
NCT05973734	Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy	Biological: Infusion of recipient T regulatory cell Biological: Infusion of concomitant Donor Derived Vertebral Bone Marrow	Stanford University University of California, San Francisco	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05973734
NCT05967455	Homologous Re-infection With Dengue 1 or Dengue 3	Biological: Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC) Biological: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)	State University of New York - Upstate Medical University U.S. Army Medical Research and Development Command Walter Reed Army Institute of Research (WRAIR)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05967455

해외 바이오의약품 임상 현황 ('23년 8월 1주)

한국바이오의약품협회, 2023.08.08.

○ 미국 62건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05956041	Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas	Drug: Pembrolizumab Drug: Mogamulizumab	University of Michigan Rogel Cancer Center Merck Sharp & Dohme LLC Hoosier Cancer Research Network	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05956041
NCT05955261	A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia	Drug: Venetoclax Drug: Azacitidine Drug: Cytarabine Drug: Gemtuzumab Ozogamicin Drug: Daunorubicin Hydrochloride Drug: Fludarabine Phosphate Drug: Idarubicin Hydrochloride Drug: Mitoxantrone Hydrochloride Drug: Etoposide Drug: Gilteritinib	St. Jude Children's Research Hospital AbbVie	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05955261
NCT05943496	Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia	Drug: Acalabrutinib Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Procedure: Echocardiography Biological: Obinutuzumab Other: Questionnaire Administration Biological: Tafasitamab	OHSU Knight Cancer Institute Oregon Health and Science University Incyte Corporation	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05943496
NCT05932654	POC Study to Evaluate BSI-045B Monotherapy and BSI-045B add-on Therapy With Dupilumab in Atopic Dermatitis	Drug: BSI-045B Drug: Dupilumab	Biosion, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05932654
NCT05913388	GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma	Drug: GB1211 Drug: Pembrolizumab Drug: Placebo	Providence Health & Services Providence Cancer Center Providence Cancer Center, Earle A. Chiles Research Institute Galecto Biotech AB	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05913388
NCT05892432	Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)	Drug: Semaglutide 3 MG [Rybelsus] Drug: Semaglutide 7 MG [Rybelsus] Drug: Placebo	University of Colorado, Denver National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05892432
NCT05891171	Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers	Drug: AB598 Drug: Zimberelimab Drug: Carboplatin Drug: Pemetrexed Drug: Fluorouracil Drug: Leucovorin Drug: Oxaliplatin	Arcus Biosciences, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05891171
NCT05877599	A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation	Biological: Autologous, engineered T Cells targeting TP53 R175H	Neogene Therapeutics, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05877599
NCT05877508	Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)	Drug: AER002 Other: Placebo	Michael Peluso, MD Aerium Therapeutics University of California, San Francisco	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05877508
NCT05866367	Measurement of Insulin Levels in Cerebral Spinal Fluid (CSF) of Healthy Adults After a Single Intranasal Dose	Drug: Low dose Regular Insulin Drug: High dose Regular insulin	HealthPartners Institute	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05866367
NCT05854498	Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer	Drug: Liposomal irinotecan Drug: TAS102 Drug: Bevacizumab	University of Wisconsin, Madison Ipsen	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05854498

해외 바이오의약품 임상 현황 ('23년 8월 1주)

한국바이오의약품협회, 2023.08.08.

○ 미국 62건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05852717	Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma	Procedure: AutoSCT Drug: GDP Drug: Epcoritamab	Dipenkumar Modi Genmab Hoosier Cancer Research Network	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05852717
NCT05821088	Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/Refractory Large B-Cell Lymphoma	Procedure: Biopsy Procedure: Biospecimen Collection Drug: Carboplatin Procedure: Computed Tomography Drug: Etoposide Drug: Ifosfamide Drug: Lenalidomide Procedure: Positron Emission Tomography Biological: Tafasitamab	David Bond, MD Ohio State University Comprehensive Cancer Center	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05821088
NCT05797246	Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)	Drug: Bevacizumab	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05797246
NCT05775471	Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer	Procedure: Biopsy Procedure: Biospecimen Collection Drug: Enfortumab Vedotin Procedure: MR Urography Procedure: Nephroureterectomy Biological: Pembrolizumab	Jonsson Comprehensive Cancer Center Merck Sharp & Dohme LLC Seagen Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05775471
NCT05757843	Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab	Diagnostic Test: Signatera ctDNA test Drug: Durvalumab	Indiana University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05757843
NCT05722327	Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer	Drug: MRTX849 Drug: Irinotecan Drug: Cetuximab	M.D. Anderson Cancer Center Mirati Therapeutics	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05722327
NCT05672251	Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Biological: Loncastuximab Tesirine Biological: Mosunetuzumab Procedure: Positron Emission Tomography	City of Hope Medical Center National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05672251
NCT05669846	Responder-derived FMT (R-FMT) and Pembrolizumab in Relapsed/Refractory PD-L1 Positive NSCLC	Drug: Fecal Microbiota Transplant (FMT) Drug: Pembrolizumab	Diwakar Davar Gateway for Cancer Research University of Pittsburgh	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05669846
NCT05655949	Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio	Drug: Gemcitabine Drug: Cisplatin Drug: Durvalumab Radiation: Yttrium-90	Beth Israel Deaconess Medical Center AstraZeneca Sirtex Medical Dana-Farber Cancer Institute	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05655949
NCT05535855	UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1	Drug: CD19 Directed CAR T Cell	University of Colorado, Denver	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05535855
NCT05377827	Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies	Biological: WU-CART-007	Washington University School of Medicine Wugen, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05377827

해외 바이오의약품 임상 현황 ('23년 8월 1주)

한국바이오의약품협회, 2023.08.08.

○ 미국 62건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05309616	Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis	Drug: Taltz	Yale University Lilly Pharmaceutical Company	Phase 2	
NCT05283109	ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM	Biological: Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine Drug: Hiltonol	Mustafa Khasraw, MBChB, MD, FRCP, FRACP National Cancer Institute (NCI) Duke University	Phase 1	
NCT05161533	Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial	Drug: Carboplatin Drug: Cisplatin Biological: Durvalumab Drug: Etoposide Radiation: Hypofractionated Radiation Therapy Other: Quality-of-Life Assessment Other: Questionnaire Administration	University of Washington AstraZeneca	Phase 2	
NCT05067595	Fecal Microbiota Transplant and Dietary Fiber Supplementation for the Treatment of Gut Graft Versus Host Disease	Procedure: Colonoscopy Biological: Fecal Microbiota Transplantation Dietary Supplement: Nutritional Supplementation Other: Survey Administration	Fred Hutchinson Cancer Center	Phase 1	
NCT04903795	Bispecific T Cell Engager BR1E for Patients With Grade IV Malignant Glioma	Drug: hEGFRvIII-CD3 (BR1E)	Duke University	Phase 1	
NCT04892875	A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers	Drug: Zimberelimab Drug: Etrumadenant Drug: Cisplatin Radiation: Radiation	Jennifer Choe Arcus Biosciences, Inc. Vanderbilt-Ingram Cancer Center	Phase 1	
NCT04881240	Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia	Biological: CD19-CAR(Mem) T-cells Drug: Cyclophosphamide Drug: Fludarabine Drug: Mesna Device: CliniMACS Procedure: Leukapheresis	St. Jude Children's Research Hospital	Phase 1	
NCT04466475	Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma	Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10 Drug: Melphalan Procedure: Peripheral Blood Stem Cell Transplantation	Fred Hutchinson Cancer Center National Cancer Institute (NCI) National Institutes of Health (NIH)	Phase 1	
NCT04153422	IVIg in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies	Drug: Panzyga IVIG Drug: Placebo	Loyola University Octapharma USA, Inc.	Phase 2	
NCT04044534	Intranasal Insulin for Posttraumatic Stress Disorder	Drug: Intranasal insulin Drug: Placebo	VA Connecticut Healthcare System	Phase 2	
NCT03552796	sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer	Other: Pharmacokinetic Study Biological: Recombinant EphB4-HSA Fusion Protein	University of Southern California National Cancer Institute (NCI)	Phase 1	
NCT05972733	Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults	Biological: HIL-214	HilleVax	Phase 2	

해외 바이오의약품 임상 현황 ('23년 8월 1주)

한국바이오의약품협회, 2023.08.08.

○ 미국 62건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05934448	Pembro Plus CAR T-cell Therapy in R/R in PMBCL	Drug: Pembrolizumab Drug: Lymphodepletion Chemotherapy Drug: Chimeric Antigen Receptor (CAR) Therapy Infusion Procedure: Leukapheresis	Jennifer Crombie, MD Merck Sharp & Dohme LLC Dana-Farber Cancer Institute	Phase 2	
NCT05856890	HepB mAb19 in Chronic Hepatitis B	Biological: HepB mAb19 Other: Sterile Saline	Rockefeller University NYU Langone Health	Phase 1	
NCT05052957	hSTAR GBM (Hematopoietic Stem Cell (HPC) Rescue for GBM)	Biological: P140K-MGMT Drug: O6-benzylguanine Radiation: Photon Based Radiotherapy Drug: temozolomide Drug: Filgrastim Drug: carmustine	Leland Metheny National Cancer Institute (NCI) Case Comprehensive Cancer Center	Phase 2	
NCT05678205	A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors	Drug: AB-201 Drug: Cyclophosphamide Drug: Fludarabine	Artiva Biotherapeutics, Inc.	Phase 1 Phase 2	
NCT05846789	Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers	Drug: Carboplatin Drug: Tocilizumab	Kathy Miller Genentech, Inc. Indiana University	Phase 2	
NCT05715229	Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy	Drug: Nivolumab Drug: Ipilimumab Drug: Carboplatin Drug: Paclitaxel Drug: Pemetrexed	Hackensack Meridian Health MedSIR	Phase 2	
NCT05588388	Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases	Drug: Bevacizumab	Kamya Sankar Genentech, Inc. University of Michigan VA Ann Arbor Healthcare System Cedars-Sinai Medical Center	Phase 2	
NCT05145816	Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis	Drug: Belantamab mafodotin 2.5 mg/kg (6 weeks) Drug: Belantamab mafodotin 2.5 mg/kg (4 weeks) Drug: Belantamab mafodotin 2.5 mg/kg (8 weeks) Drug: Belantamab mafodotin 1.9 mg/kg (8 weeks) Drug: Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages	University of Texas Southwestern Medical Center GlaxoSmithKline	Phase 1 Phase 2	
NCT05545072	Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)	Drug: Dupilumab 300 MG/2 ML Subcutaneous Solution Drug: Placebo	Emory University Sanofi	Phase 3	
NCT05896163	A Study to Learn About the Effects of Two Study Medicines (Maplirpcept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma	Drug: maplirpcept (PF-07901801) Drug: Glofitamab Drug: Obinutuzumab	Pfizer Hoffmann-La Roche	Phase 1 Phase 2	
NCT05835206	Further MT for Antibiotic-Resistant Bacterial Colonization in Inpatients	Drug: Microbiome Therapeutic Drug: Placebo	Emory University Centers for Disease Control and Prevention	Phase 2	
NCT05813327	Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma	Drug: ADI PEG20 Drug: Ifosfamide Radiation: Radiotherapy Drug: Mesna	Washington University School of Medicine Polaris Group	Phase 1 Phase 2	

해외 바이오의약품 임상 현황 ('23년 8월 1주)

한국바이오의약품협회, 2023.08.08.

○ 미국 62건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05921903	A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 50 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above	Biological: RSVPreF3 OA Investigational Vaccine	GlaxoSmithKline	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05921903
NCT05856331	Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema	Drug: INBRX-101 Drug: Zemaira	Inhibrx, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05856331
NCT05638581	Trauma Resuscitation With Low-Titer Group O Whole Blood or Products	Biological: LTOWB Biological: Components	University of Alabama at Birmingham National Heart, Lung, and Blood Institute (NHLBI) The University of Texas Health Science Center, Houston	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05638581
NCT05695391	SCOPE HIM SCOPE HIM	Biological: Coagulation Factor VIIa (Recombinant)	Laboratoire français de Fractionnement et de Biotechnologies	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05695391
NCT05935098	A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors	Drug: BGB-A3055 Drug: Tislelizumab	BeiGene	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05935098

○ 영국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05208242	Strong Albumin Solutions in Patients With Septic Shock	Drug: hyperoncotic human albumin solution Drug: Buffered crystalloid solutions	Manchester University NHS Foundation Trust University of Manchester	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05208242

○ 프랑스 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05935098	A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors	Drug: BGB-A3055 Drug: Tislelizumab	BeiGene	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05935098

○ 독일 6건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05937295	FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition	Drug: Fusion-VAC-XS15	University Hospital Tuebingen	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05937295
NCT05958121	IMA402 T Cell-Engaging Receptor Molecule (TCER) in Recurrent and/or Refractory Solid Tumors	Biological: IMA402 (Phase Ia) Biological: IMA402 (Phase Ib) Biological: IMA402 (Phase II)	Immatics Biotechnologies GmbH	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05958121
NCT05904106	Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML	Drug: Venetoclax plus Azacitidine Drug: standard of care chemotherapy plus gemtuzumab ozogamicin	Technische Universität Dresden University Hospital Heidelberg AbbVie	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05904106

해외 바이오의약품 임상 현황 ('23년 8월 1주)

한국바이오의약품협회, 2023.08.08.

○ 독일 6건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05704829	NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer	Drug: Trastuzumab deruxtecan Drug: Standard-of-Care	West German Study Group AstraZeneca	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05704829
NCT05257083	A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucl Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma	Drug: Daratumumab Drug: Bortezomib Drug: Lenalidomide Drug: Dexamethasone Drug: Cilta-cell Drug: Cyclophosphamide Drug: Fludarabine	European Myeloma Network Janssen Research & Development, LLC	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05257083
NCT05921903	A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 50 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above	Biological: RSVPreF3 OA Investigational Vaccine	GlaxoSmithKline	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05921903

○ 중국 30건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05949619	A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors	Drug: BL-M02D1	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05949619
NCT05949606	A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer	Drug: SI-B001 Drug: SI-B003	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05949606
NCT05944978	A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies	Drug: GNC-035	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05944978
NCT05455034	Single-cell Sequencing of BLF to Guide the Treatment of Radiation Pneumonitis or Immune Checkpoint Inhibitor Pneumonitis	Genetic: single-cell sequencing	Xinqiao Hospital of Chongqing	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05455034
NCT05975463	Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy	Procedure: HAIC Drug: Adebrelimab Drug: Bevacizumab	HuiKai Li Tianjin Medical University Cancer Institute and Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05975463
NCT05975307	Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation	Drug: Toripalimab Drug: Gemcitabine Drug: Cisplatin Drug: Carboplatin Radiation: Intensity-modulated radiation therapy	Sun Yat-sen University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05975307
NCT05975151	Efficacy and Safety of Pseudomonas Aeruginosa for High-risk Non-muscle Invasive Bladder Cancer	Drug: Pseudomonas aeruginosa	Qilu Hospital of Shandong University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05975151
NCT05974059	Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer	Drug: Oxaliplatin Drug: Capecitabine Drug: Cadonilimab	Tianjin Medical University Cancer Institute and Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05974059

해외 바이오의약품 임상 현황 ('23년 8월 1주)

한국바이오의약품협회, 2023.08.08.

○ 중국 30건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05970666	Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma	Drug: TACE with adebrelimab and bevacizumab	The First Affiliated Hospital of Xiamen University Jiangsu HengRui Medicine Co., Ltd.	Phase 2	
NCT05968508	A Randomized, Double-blind, Single-dose, Two-arm Parallel Study to Compare the Pharmacokinetics and Safety of BAT1806 Prefilled Subcutaneous Injection With RoActemra® in Healthy Chinese Male Subjects	Drug: BAT1806 prefilled subcutaneous injection/RoActemra® (from EU)	Bio-Thera Solutions	Phase 1	
NCT05965856	A Study of BL-B01D1+SI-B003 in the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors	Drug: BL-B01D1 Drug: SI-B003	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 2	
NCT05962450	Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy	Biological: iNKT Cells Drug: PD-1 Drug: Regorafenib	Beijing YouAn Hospital Beijing Gene Key Life Technology Co., Ltd.	Phase 2	
NCT05953623	Intra-arterial Albumin Infusion After Endovascular Therapy for Stroke Patients	Biological: Albumin	Tianjin Huanhu Hospital	Phase 1	
NCT05953168	T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients	Drug: Trastuzumab Deruxtecan	Fudan University	Phase 2	
NCT05940961	Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL	Drug: Inotuzumab Ozogamicin	Sheng-Li Xue, MD Jining Medical University The Second People's Hospital of Huai'an First Affiliated Hospital Bengbu Medical	Phase 2	
NCT05926427	Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement	Drug: Orelabrutinib Drug: Rituximab Drug: Chemotherapy	Ruijin Hospital	Phase 2	
NCT05910177	Neoadjuvant Treatment of Neuroendocrine Cervix Carcinoma With Karelizumab Combined With Etoposide and Cisplatin	Drug: Karelizumab combined with etoposide and cisplatin	Fujian Cancer Hospital	Phase 2	
NCT05909241	A Study of BA1202 in Patients With Advanced Solid Tumors	Drug: BA1202	Shandong Boan Biotechnology Co., Ltd	Phase 1	
NCT05896007	Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT	Drug: Zanubrutinib Drug: Rituximab Drug: Methotrexate Drug: Temozolomide	Ruijin Hospital	Phase 2	
NCT05887726	Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors	Drug: Zanubrutinib Drug: Rituximab Drug: Cyclophosphamide Drug: Epirubicin Drug: Vincristine Drug: Prednisone	Liaoning Tumor Hospital & Institute	Phase 2	
NCT05821361	HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma	Drug: HAIC+Cadonilimab+Bevacizumab	Tianjin Medical University Cancer Institute and Hospital	Phase 2	
NCT05798793	Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma	Drug: Camrelizumab plus TP Drug: TP	Hospital of Stomatology, Wuhan University Jiangsu HengRui Medicine Co., Ltd.	Phase 3	

해외 바이오의약품 임상 현황 ('23년 8월 1주)

한국바이오의약품협회, 2023.08.08.

○ 중국 30건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05775705	L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH	Drug: L-DEP and PD-1 antibody	Beijing Friendship Hospital	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05775705
NCT05648006	First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer	Biological: OH2 Drug: Capecitabine Drug: Bevacizumab	Binhui Biopharmaceutical Co., Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05648006
NCT05496166	The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer	Combination Product: chemotherapy and SHR-1316(Adebrelimab) combined with surgery or radiotherapy	Shanghai Pulmonary Hospital, Shanghai, China Jiangsu HengRui Medicine Co., Ltd.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05496166
NCT05296603	Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer	Drug: IBI-322 Plus Lenvatinib	Hunan Province Tumor Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05296603
NCT05956587	A Study of BL-B01D1+SI-B003 in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors	Drug: BL-B01D1 Drug: SI-B003	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05956587
NCT05975645	A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).	Drug: Penpulimab injection Drug: TQB2618 injection Drug: Anlotinib Hydrochloride Capsules	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05975645
NCT05924750	A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia	Drug: BL-M11D1	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05924750
NCT05970289	Investigate the Efficacy and Safety of BR11-835 (VIR-2218) and PEG-IFN α Combination Therapy in Chronic HBV Patients	Biological: PEG-IFN α Drug: BR11-835	Brii Biosciences Limited Vir Biotechnology, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05970289

○ 일본 4건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05932641	Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult Participants	Biological: AZD3152 (Cohort 1) Biological: Placebo (Cohort 1) Biological: AZD3152 (Cohort 2) Biological: Placebo (Cohort 2) Biological: AZD3152 (Cohort 3) Biological: Placebo (Cohort 3)	AstraZeneca	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05932641
NCT05896163	A Study to Learn About the Effects of Two Study Medicines (Maplirpcept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.	Drug: maplirpcept (PF-07901801) Drug: Glofitamab Drug: Obinutuzumab	Pfizer Hoffmann-La Roche	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05896163
NCT05710692	Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease	Drug: PRX-102 1 mg/kg every 2 weeks Drug: PRX-102 2 mg/kg every 4 weeks	Chiesi Farmaceutici S.p.A. ICON plc	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05710692
NCT05921903	A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 50 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above	Biological: RSVPreF3 OA Investigational Vaccine	GlaxoSmithKline	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05921903